RUBYMILLS evidence report
Evidence date: 2026-10-01. Research observations only.
What can I do with this stock?
Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.
Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.
Today: intraday
Evidence unavailable
No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.
- No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.
Next week: five trading sessions
No qualifying opportunity
No candidate with a primary five-session horizon in the coherent source run.
- No candidate with a primary five-session horizon in the coherent source run.
Long term: one to three years
Research only
A financial screen alone does not establish an investment recommendation.
- A current, source-backed thesis and valuation review is required.
Investment evidence
- Statement coverage
- FULL_STATEMENTS
- Financial source retrieved
- 2026-09-29T23:41:33.611934+00:00
Metrics
- latest_annual_period
- 2026-03-31
- revenue
- 3585956000.0
- net_income
- 435594000.0
- operating_cash_flow
- 630487000.0
- free_cash_flow
- -485698000.0
- total_assets
- 12163524000.0
- total_liabilities
- 5420047000.0
- total_equity
- 6743474000.0
- cash
- 138542000.0
- total_debt
- 3758787000.0
- revenue_growth
- 0.477479897621665
- earnings_growth
- 0.029468833087149093
- net_margin
- 0.12147220992114795
- roe
- 0.06459489574661369
- debt_to_equity
- 0.5573962322684124
- cash_conversion
- 1.447418926798808
- free_cash_flow_margin
- -0.1354444951360251
- trailing_pe
- 22.54
- forward_pe
- Not supplied
- peg_ratio
- Not supplied
- price_to_book
- Not supplied
- dividend_yield
- Not supplied
Other positional research
No qualifying opportunity
No candidate at another positional horizon in the coherent source run.
- No candidate at another positional horizon in the coherent source run.
Decision provenance and limitations
- Decision ID
- decision-f7dbfffa19a5948b6bdc1f4b5078f5e2597bda6c161096eba890a410851d6ee7
- Policy
- stock-decisions-v1
- Evidence bundle hash
- 0b81a95118b92113d9699ed3322ec942cb80ecf23c62ed3972d2a308166b55fa
- market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
- validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
- financial-statements: 073b6ce149618debf6ef2b6580fca93acdbd0883321c04a908a817399aa7cf28
- daily-price: 7db5b9fd97b0ab18155b545d7adf6dd9c8925eca58206fbe5097e0aab77f7927
- Conditional research decisions are not orders or personalized position sizes.
- Scenario payoffs are assumptions, not probabilities or expected returns.
- A stop price does not guarantee a maximum loss through a gap or illiquidity.
Download the decision evidence as JSON
Numerical report available. Evidence briefing is queued or awaiting retry.
Cached observations and evidence limits
- Price source verification: REPAIRED.
- The cached closing price on 2026-10-01 was INR 499.65.
- The trailing 5-session price return was 1.02%.
- The trailing 20-session price return was 26.60%.
- The trailing 60-session price return was 44.30%.
- The trailing 250-session price return was 121.68%.
- Average cached traded value over twenty sessions was INR 20,466,820.
- The closing price was -2.14% below its highest close in the available trailing year.
- Fundamental coverage is FULL_STATEMENTS; retrieved 2026-09-29T23:41:33.611934+00:00 from EODHD.
- The cached financial metric latest annual period is 2026-03-31.
- The cached financial metric revenue growth is 0.477479897621665.
- The cached financial metric net margin is 0.12147220992114795.
- The cached financial metric roe is 0.06459489574661369.
- The cached financial metric debt to equity is 0.5573962322684124.
- The cached financial metric cash conversion is 1.447418926798808.
- The cached financial metric free cash flow margin is -0.1354444951360251.
- Historical observations do not establish future returns. No verified current news or catalyst evidence is supplied.